Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Shahid Beheshti University of Medical Sciences

Status and phase: Completed; Phase 4

Conditions: Endothelial Graft Rejection

Treatments: Drug: Sandimmune; Drug: Artelose

Study type: Interventional

Funder types: Other

Identifiers

NCT01028443

8546

Details and patient eligibility

About

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Penetrating keratoplasty in eyes without vascularization

Exclusion criteria

• History of previous intraocular surgery

Trial design

0 participants in 2 patient groups, including a placebo group

Cyclosporine A 2%

Active Comparator group

Treatment:

Drug: Sandimmune

Artificial tears

Placebo Comparator group

Treatment:

Drug: Artelose